Education Blog for Healthcare Professionals

Archive for the ‘Venous Clots’ Category

IVC Filters, May-Thurner Syndrome, Pelvic Vein Stents

| Anatomy, Deep Vein Thrombosis (DVT), IVC filters, Postthrombotic syndrome, Therapy, Uncategorized | Comments Off on IVC Filters, May-Thurner Syndrome, Pelvic Vein Stents

Stephan Moll, MD writes… An article for patients discussing (a) IVC filters, (b) narrowing of the main left pelvic vein (May-Thurner syndrome) and (c) pelvic venous stents has just been published (http://circ.ahajournals.org/content/133/6/e383.full.pdf).  Color images of anatomy, filters and stents are included as visual aids.  The article may be helpful as handout material for patients in clinic.

Reference:  Carroll S, Moll S. Circulation. 2016;133:e383-e387

 

Last updated: Feb 18th, 2016

Thrombophilia – Information Handout for Patients

| Acquired risk factors, Antiphospholipid antibodies, APC resistance, Clots in unusual locations, Deep Vein Thrombosis (DVT), Factor V Leiden, Homocysteine, MTHFR, Inherited, Protein C deficiency, Protein S deficiency, Prothrombin 20210 mutation, Pulmonary Embolism, Thrombophilias, Uncategorized, Venous Clots, Whom to test, Women and blood clots | Comments Off on Thrombophilia – Information Handout for Patients

Stephan Moll, MD writes… An information article on various aspects of thrombophilia, written for patients and family members, was published today – available here – as a Vascular Disease Patient Information Page in the journal Vascular Medicine.  It addresses (a) in which patient with venous thromboembolism to consider thrombophilia  testing, (b) what tests might be appropriate to do, (c) how the test results might influence length of anticoagulation therapy (d), what contraceptives are safe to use in women with a history of DVT or PE or thrombophilia, and (e)  in which family members to consider thrombophilia testing.  This article can be used as an education handout for patients in clinic or the hospital who have DVT, PE, venous thrombosis in unusual locations, or an established thrombophilia.

 

Disclosures:  None

Last updated: April 1st, 2015

Catheter-Associated DVT of Arm and Neck in Cancer Patients: ISTH Guidance

| Clots in unusual locations, Deep Vein Thrombosis (DVT), Uncategorized, Venous Clots | Comments Off on Catheter-Associated DVT of Arm and Neck in Cancer Patients: ISTH Guidance

Stephan Moll, MD writes… This week (Feb 18th, 2014) a guidance document on the prevention and management of catheter-associated upper extremity (brachial, axillary, subclavian, and brachiocephalic veins) and neck (internal jugular) DVT was published by the International Society for Thrombosis and Haemostasis (ISTH) [ref 1].  The authors acknowledge that optimal long-term management of catheter-associated DVT has not been established.  The key recommendations: Read the rest of this entry »

Handout for Your Patients in Clinic – Which Anticoagulant to Use for DVT and PE

| Anticoagulants, Deep Vein Thrombosis (DVT), Eliquis, Pradaxa (dabigatran), Pulmonary Embolism, Uncategorized, Warfarin (Coumadin), Xarelto (Rivaroxaban) | Comments Off on Handout for Your Patients in Clinic – Which Anticoagulant to Use for DVT and PE

Stephan Moll, MD writes…  Patients who are on warfarin for a history of DVT or PE  may inquire whether a switch to one of the  new oral anticoagulants is appropriate.  Similarly, many physicians initiate this discussion with their patients.

This is, obviously, a detailed discussion and an individualized decision with a number of factors to be considered.  We have developed a two-page “Comparison of Oral Blood Thinners”  handout for patients, to assist with and summarize the discussion.  This sheet allows a structured  discussion with the patient about the pros and cons of the various anticoagulant choices.  The reader is welcome to print this resource and use it as a handout for his/her patients.

Disclosure:  I have been a consultant for  Boehringer-Ingelheim, Daiichi, and Janssen.

Last Updated:  Dec 19th, 2013

Pulmonary Hypertension due to PE: New Drug Approved

| Pulmonary Embolism, Therapy, Uncategorized | Comments Off on Pulmonary Hypertension due to PE: New Drug Approved

 Stephan Moll, MD writes…

On Oct 8th, 2013 the FDA approved Adempas® (riociguat), a new oral drug to treat pulmonary hypertension.  The drug is a guanylate cyclase stimulator that leads to arteries dilatation. It is intended for:

International Coagulation Meeting (ISTH 2013): Highlights

| Anticoagulants, Deep Vein Thrombosis (DVT), Eliquis, Inherited, Pradaxa (dabigatran), Pulmonary Embolism, Therapy, Thrombophilias, Uncategorized, Xarelto (Rivaroxaban) | Comments Off on International Coagulation Meeting (ISTH 2013): Highlights

Stephan Moll, MD writes…  A major international coagulation conference, the bi-annual meeting of the International Society for Thrombosis and Haemostasis (ISTH; www.isth.org), took place in Amsterdam, Holland, from June 29th to July 4th, 2013.  The clinically relevant highlights about thrombosis and anticoagulation are summarized below. Read the rest of this entry »

New Publication: Eliquis (Apixaban) is Effective and Safe in DVT and PE

| Deep Vein Thrombosis (DVT), Eliquis, Pulmonary Embolism, Uncategorized, Venous Clots | Comments Off on New Publication: Eliquis (Apixaban) is Effective and Safe in DVT and PE

Stephan Moll, MD writes…  

An important study (AMPLIFY trial) was published today in the New England Journal of Medicine [ref 1]: In a large study of 5395 patients with acute DVT or PE, Eliquis (apixaban) was as effective as warfarin and caused less major bleeding. Read the rest of this entry »

Top 10 Publications on Thrombosis and Anticoagulation from 2012

| Arterial Clots, Aspirin, Plavix, Aggrenox, Tiklid, Persantine, Deep Vein Thrombosis (DVT), Eliquis, Other topics, Pradaxa (dabigatran), Pulmonary Embolism, Uncategorized, Venous Clots, Warfarin (Coumadin), Xarelto (Rivaroxaban) | Comments Off on Top 10 Publications on Thrombosis and Anticoagulation from 2012

Stephan Moll writes…

2012 has been a year with significant progress in the field of venous thromboembolism and anticoagulation.  The three most noteworthy, clinically relevant developments were probably (a) the publication of the new ACCP (American College of Chest Physician) guidelines on antithrombotic therapy in February 2012; (b)  The FDA-approval of rivaroxaban (Xarelto) in November 2012 for the acute treatment of venous thromboembolism (VTE) and long-term secondary prevention; and (c) The FDA-approval of apixaban (Eliquis) in December 2012 for atrial fibrillation and the prevention of arterial thromboembolism.  Here I have listed and summarized the 10 top publications of 2012  in the field of venous thromboembolism and anticoaguation as I see them – the ones clinically most relevant. 

 

Disclosure: I have consulted for Janssen, Boehringer-Ingelheim and Daiichi.

Last updated: Feb 7th, 2013

 

TTP with I.V. Use of Pain Medication OpanaER

| Clots in unusual locations, Uncategorized | Comments Off on TTP with I.V. Use of Pain Medication OpanaER

Stephan Moll, MD writes… 

The CDC published an alert on Oct 26th, 2012, that they are investigating 12 cases of TTP (thrombotic thrombocytopenic purpura) in drug users who injected intravenously the opioid pain medication Opana ER® (oxymorphone extended-release), a medication made as a tablet and meant for oral use. The tablet was pulverized by the drug users to allow i.v. injection (detailed CDC alert here). 

Relevance for clinicans involved in the care of patients with TTP:  Inquire in the history taking about drug abuse and injection of Opana ER.

Last updated: Oct 29th, 2012